Eye injection injury lawsuits represent a growing category of personal injury claims involving medications and treatments administered directly into the eye. These lawsuits typically allege that pharmaceutical manufacturers, medical device companies, or healthcare providers failed to adequately warn patients about serious side effects—including vision loss, blindness, or permanent eye damage—resulting from injected medications. For example, over 120 cases have been filed against GLP-1 drug manufacturers like Novo Nordisk for nonarteritic anterior ischemic optic neuropathy (NAION), an eye stroke condition that can cause permanent vision loss in diabetic patients and people using weight-loss medications.
Eye injection injuries can occur through multiple pathways: direct medication toxicity, improper injection technique, contaminated products, or inadequate informed consent. The litigation landscape includes claims against major pharmaceutical companies (Novo Nordisk’s Ozempic and Wegovy, Novartis’s Beovu), chemotherapy manufacturers (Sanofi-Aventis’s Taxotere), and individual healthcare providers for injuries related to intravitreal injections—a common treatment method for retinal diseases, diabetic eye conditions, and macular edema. The scope of eye injection injury litigation has expanded significantly in recent years, with multiple multidistrict litigations (MDLs) now active and state court filings continuing to accumulate. Understanding what these cases involve, who can file, and what outcomes have been achieved is essential for patients who believe they suffered preventable eye damage.
Table of Contents
- What Are Eye Injection Injuries and How Do They Lead to Lawsuits?
- GLP-1 Drug Vision Loss Litigation—The Largest Category
- Beovu and Newer Injectable Medications in Litigation
- How Court Decisions and Settlements Have Shaped Eye Injection Litigation
- Intravitreal Injection Complications and Why Physicians Face Lawsuits
- What Intravitreal Injection Statistics Reveal About Litigation Patterns
- The Future of Eye Injection Injury Litigation and Emerging Claims
- Conclusion
What Are Eye Injection Injuries and How Do They Lead to Lawsuits?
Eye injection injuries occur when medications or treatments administered directly into the eye—typically intravitreal injections delivered behind the retina—cause unexpected or inadequately warned harm. Common injectable medications include corticosteroids like triamcinolone, biologics like brolucizumab and bevacizumab (Avastin), and newer compounds like brolucizumab and pegaptanib. While intravitreal injections are standard treatments for conditions such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, they carry inherent risks including infection, retinal detachment, cataract formation, and vision loss. Lawsuits arise when patients allege that pharmaceutical manufacturers or physicians failed to adequately disclose these risks before treatment, or when side effects occur at rates higher than disclosed in the medication’s label and warnings.
A comprehensive review of intravitreal injection litigation from 2000 to 2025 identified 60 total lawsuits, with triamcinolone cited in 33.3% of cases, brolucizumab in 13.3%, and bevacizumab in another 13.3%. Geographically, Louisiana accounted for 32% of these cases and California for 20%, suggesting regional variation in litigation patterns and possibly in physician practices or adverse event reporting. The distinction between a medication side effect and a basis for litigation hinges on adequate warning and disclosure. Patients who can demonstrate that a reasonable physician would not have recommended the injection had they known the actual risk of serious vision loss—particularly when the warning label downplayed or omitted that risk—have stronger claims. However, proving negligence or failure to warn requires expert testimony establishing that the manufacturer either knew or should have known about the increased risk.
GLP-1 Drug Vision Loss Litigation—The Largest Category
The most significant volume of current eye injection injury litigation involves GLP-1 receptor agonists—a class of diabetes and weight-loss medications including Novo Nordisk’s Ozempic, Wegovy, and Mounjaro. As of May 2026, these cases center on nonarteritic anterior ischemic optic neuropathy (NAION), a condition in which reduced blood flow to the optic nerve causes sudden, often permanent vision loss. The litigation includes 86 total Mounjaro cases filed in MDL 3163 related to NAION, representing an increase of 13 cases during the latest litigation update. Additionally, 73 lawsuits remain pending in the same MDL involving GLP-1 receptor agonists and NAION claims, and a separate multicounty litigation against Novo Nordisk includes 40 cases filed for Ozempic and Wegovy vision loss. Across all manufacturers and state courts, over 120 total GLP-1 vision loss cases have been filed to date, making this the dominant category of active eye injection–related litigation.
The legal theory underlying these claims is that GLP-1 drug manufacturers knew or should have known that their products increased NAION risk in susceptible populations—particularly older diabetic patients and those with pre-existing optic nerve vulnerability—yet failed to adequately warn physicians and patients. Patients who experienced sudden vision loss weeks or months after starting a GLP-1 medication argue they would not have consented to treatment had they understood this specific risk. A critical limitation in GLP-1 litigation is establishing causation. NAION can occur spontaneously, particularly in older populations, making it challenging to prove that a specific GLP-1 drug directly caused any individual’s vision loss rather than being a coincidental temporal association. Courts have appointed leadership in these cases: Judge Marston designated Jonathan Orent as Co-Lead Counsel and Grace Chandler as an executive committee member for the vision loss MDL, signaling that judges expect significant discovery and potentially multi-year litigation. Outcomes remain unknown, as no trials or settlements have been reached in GLP-1 NAION litigation as of May 2026.
Beovu and Newer Injectable Medications in Litigation
Beovu (brolucizumab), manufactured by Novartis, is a newer injectable medication used to treat age-related macular degeneration. Unlike GLP-1 litigation, which involves multiple consolidated MDLs, Beovu vision loss lawsuits have not been consolidated into multidistrict litigation as of April 2026. Lawyers handling these cases expect only a few hundred claims total, and no trials or court-approved settlements have been reached to date. The primary legal allegation is that Novartis failed to adequately warn about potential vision-related side effects, particularly retinal vasculitis and other inflammatory complications associated with Beovu injections. The absence of an MDL consolidation for Beovu cases suggests that individual state court litigation will proceed separately, potentially resulting in inconsistent verdicts and varying settlement amounts across jurisdictions.
This fragmented approach contrasts with the coordinated federal multidistrict litigation used for higher-volume claims like GLP-1 cases. For plaintiffs considering a Beovu vision loss claim, the lack of MDL consolidation means claims may take longer to resolve, as there is no centralized case management, coordinated discovery, or pooled expert testimony to streamline litigation. Beovu represents an emerging category of eye injection injuries from newer biologic medications. As manufacturers develop new intravitreal therapies, the regulatory pathway and initial warning labels may not fully capture rare but serious complications that emerge once widespread use begins. Patients injured by Beovu or similar newer eye injectables should consult with attorneys experienced in pharmaceutical litigation, as these cases require navigating individual state court systems rather than consolidated federal proceedings.
How Court Decisions and Settlements Have Shaped Eye Injection Litigation
A critical turning point in eye injection litigation occurred in May 2026, when Judge Jane Triche Milazzo denied a summary judgment motion filed by Sanofi-Aventis US LLC in Taxotere (docetaxel) eye injury cases. Taxotere is a chemotherapy drug used to treat various cancers, and while its primary mechanism of action is anti-cancer activity, patients have alleged that the drug causes eye injuries including tearing of the eyelids and lacrimal duct stenosis (narrowing of the tear duct). Sanofi’s attempt to dismiss the litigation via summary judgment failed, meaning the litigation continues despite the manufacturer’s argument that the evidence does not support plaintiffs’ claims. The court’s decision preserved expert testimony establishing that Taxotere caused eye injuries in at least some plaintiffs, even though part of one expert’s testimony was excluded.
This outcome demonstrates that judges have not found eye injury claims against pharmaceutical manufacturers to be frivolous or unsupported, and litigation will proceed to trial or settlement negotiations. For plaintiffs with Taxotere eye injury claims, the May 2026 ruling suggests that cases are viable and likely to survive early dismissal attempts, though the litigation process remains protracted and uncertain. A major limitation in eye injection litigation generally is the difficulty of achieving large, company-wide settlements or verdicts. Historical data from intravitreal injection lawsuits shows that outcomes vary dramatically: 50% of decided cases favored the defendant, 25% resulted in settlements with undisclosed amounts, 12.5% were awarded to plaintiffs with an average settlement of $1,607,683, and 12.5% had unknown outcomes. This variance means that some plaintiffs recover substantial compensation while others lose entirely, and the litigation outcome depends heavily on the specific medication, jurisdiction, and quality of evidence.
Intravitreal Injection Complications and Why Physicians Face Lawsuits
Intravitreal injections, while standard care for many retinal diseases, carry inherent risks that become sources of litigation when injuries occur. A comprehensive review identified that 13% of intravitreal injection lawsuits (8 cases) were filed against physicians rather than manufacturers, typically alleging improper injection technique, failure to maintain sterile conditions, or delayed recognition and treatment of injection-related complications. The typical defendant physician in these cases was a male attending physician (75% of cases) working in a Veterans Affairs setting (63% of cases), with residents involved in 38% of cases. The pattern of physician defendants in Veterans Affairs settings suggests that high-volume, busy clinical environments may increase injection-related injury risk.
Veterans Affairs hospitals often handle large patient populations with limited resources, and if injections are performed by residents or fellows under attending supervision, the risk of technical error or inadequate post-injection monitoring may increase. Patients injured by physician error during intravitreal injections can pursue medical malpractice claims separately from or in addition to claims against medication manufacturers. A significant limitation for patients pursuing claims against physicians is that many eye injection injuries occur despite technically correct injection technique and standard sterile conditions. NAION, for example, can occur from systemic factors (blood pressure, blood sugar control, blood viscosity) rather than from the injection itself, making it difficult to establish that a specific physician’s technique caused the injury. Plaintiffs alleging physician negligence must demonstrate not only that an adverse event occurred, but that the physician’s conduct fell below the standard of care, which requires expert testimony and detailed medical records.
What Intravitreal Injection Statistics Reveal About Litigation Patterns
A systematic review of 60 intravitreal injection lawsuits filed between 2000 and 2025 reveals critical patterns about which medications and settings generate the most claims. Triamcinolone, a corticosteroid used to treat macular edema and diabetic eye disease, was implicated in 33.3% of cases, making it the most frequently litigated intravitreal medication. Brolucizumab and bevacizumab each appeared in 13.3% of cases, while other medications and unknown agents made up the remainder.
Male patients comprised 43% of plaintiffs, and outcomes were highly variable: half of decided cases favored defendants, a quarter settled with undisclosed amounts, and the remaining quarter was split between plaintiff awards and unknown outcomes. Geographic concentration of intravitreal injection litigation in Louisiana (32% of cases) and California (20% of cases) suggests that these states either have higher rates of adverse events, more aggressive litigation practices, or both. The concentration in Louisiana is particularly noteworthy and may reflect the state’s civil justice system, medical practices in that region, or the presence of law firms specializing in eye injury claims. For patients considering intravitreal injection litigation, the statistics indicate that successful outcomes are far from guaranteed, and settlement or award amounts vary widely depending on the specific facts and jurisdiction.
The Future of Eye Injection Injury Litigation and Emerging Claims
As pharmaceutical manufacturers continue to develop new intravitreal therapies and GLP-1 drugs gain wider use for weight loss (beyond their original diabetes indication), eye injection injury litigation is likely to expand. The current wave of GLP-1 NAION litigation, with over 120 cases filed and multiple MDLs active, establishes a template for how future medications will be litigated if serious eye-related side effects emerge. Regulatory agencies may update warning labels or implement post-marketing surveillance programs to detect vision-loss signals earlier, potentially reducing the number of patients injured before risks become widely known.
The outcome of GLP-1 litigation will likely influence how severely pharmaceutical companies warn about eye risks in future injectable medications, and settlements or verdicts in those cases may establish benchmarks for compensation in subsequent eye injury claims. Patients considering any new injectable medication—whether for diabetes, weight loss, eye disease, or cancer—should carefully review the risks of vision loss or eye injury in the medication’s information, and should report any vision changes to their healthcare provider immediately. For those who have suffered eye injuries from injectable medications, consulting with a litigation attorney early in the process is essential, as the statute of limitations for filing claims is finite and evidence degrades over time.
Conclusion
Eye injection injury lawsuits span multiple medication categories—GLP-1 drugs causing NAION, Beovu causing retinal inflammation, Taxotere causing lacrimal duct damage, and numerous intravitreal injections causing technical complications—and reflect the reality that even standard, FDA-approved treatments can cause serious, permanent harm when manufacturers fail to adequately warn or when physicians use improper technique. The current litigation landscape is dominated by GLP-1 NAION claims, with over 120 cases filed and multiple MDLs consolidating claims for coordinated discovery and potential settlement negotiations. However, outcomes remain uncertain, as no trials or settlements have been reached in the largest categories of cases.
If you believe you suffered vision loss, blindness, or permanent eye damage following an injection of a pharmaceutical product or medical treatment, you may be eligible to pursue a claim. Contact an attorney experienced in pharmaceutical litigation and mass torts to discuss your case, gather your medical records, and understand the statute of limitations in your state. Early consultation is critical, as evidence must be preserved and claims must be filed within the time frame specified by your state’s laws.